Renata Abrahão1,2, Daphne Y Lichtensztajn2, Raul C Ribeiro3, Neyssa M Marina4, Ruth H Keogh5, Rafael Marcos-Gragera6, Sally L Glaser2,7, Theresa H M Keegan2,7. 1. Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. 2. Cancer Prevention Institute of California, Fremont, California. 3. Department of Oncology, Leukemia and Lymphoma Division, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Department of Pediatric Hematology/Oncology, Lucile Packard Children's Hospital, Stanford, California. 5. Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK. 6. Epidemiology Unity and Cancer Registry of Girona, Institute for Biomedical Research of Girona, Girona, Spain. 7. Department of Health Research and Policy, Division of Epidemiology, Stanford, California.
Abstract
BACKGROUND: Despite advances in treatment, survival from acute lymphoblastic leukemia (ALL) remains lower among non-White children than White children in the US. We investigated the association of race/ethnicity and socioeconomic status (SES) with survival. PROCEDURES: We analyzed 9,295 Californian children (3,251 Whites, 4,890 Hispanics, 796 Asians, and 358 Blacks) aged ≤ 19 years diagnosed with a first primary ALL during 1988-2011. We used the Kaplan-Meier method to estimate survival at 1, 5, and 10 years after diagnosis for three calendar periods. Hazard ratios of death for race/ethnicity, SES, and clinical factors were estimated by Cox regression models. RESULTS: Median follow-up time was 7.4 years (range 0-25 years). Over time, survival after ALL improved steadily, but inequalities persisted across races/ethnicities. Five-year survival (95% confidence interval) was 85.0% (83.6-86.2) for White, 81.4% (78.3-84.0) for Asian, 79.0% (77.8-80.2) for Hispanic, and 74.4% (69.4-78.8) for Black children. In multivariable-adjusted models, the hazard of death was increased by 57% among Black, 38% among Hispanic, and 33% among Asian children compared with White children. Patients residing in the lowest SES neighborhoods at diagnosis had a 39% increased risk of death relative to those living in higher SES neighborhoods. CONCLUSION: Despite significant improvements in survival, non-White children and children residing in low SES neighborhoods experienced worse survival even after adjusting for potential confounders. Our findings highlight the need to capture specific information on disease biology, treatment, and treatment adherence to better understand the predictors of lower survival in minority and low SES groups.
BACKGROUND: Despite advances in treatment, survival from acute lymphoblastic leukemia (ALL) remains lower among non-White children than White children in the US. We investigated the association of race/ethnicity and socioeconomic status (SES) with survival. PROCEDURES: We analyzed 9,295 Californian children (3,251 Whites, 4,890 Hispanics, 796 Asians, and 358 Blacks) aged ≤ 19 years diagnosed with a first primary ALL during 1988-2011. We used the Kaplan-Meier method to estimate survival at 1, 5, and 10 years after diagnosis for three calendar periods. Hazard ratios of death for race/ethnicity, SES, and clinical factors were estimated by Cox regression models. RESULTS: Median follow-up time was 7.4 years (range 0-25 years). Over time, survival after ALL improved steadily, but inequalities persisted across races/ethnicities. Five-year survival (95% confidence interval) was 85.0% (83.6-86.2) for White, 81.4% (78.3-84.0) for Asian, 79.0% (77.8-80.2) for Hispanic, and 74.4% (69.4-78.8) for Black children. In multivariable-adjusted models, the hazard of death was increased by 57% among Black, 38% among Hispanic, and 33% among Asian children compared with White children. Patients residing in the lowest SES neighborhoods at diagnosis had a 39% increased risk of death relative to those living in higher SES neighborhoods. CONCLUSION: Despite significant improvements in survival, non-White children and children residing in low SES neighborhoods experienced worse survival even after adjusting for potential confounders. Our findings highlight the need to capture specific information on disease biology, treatment, and treatment adherence to better understand the predictors of lower survival in minority and low SES groups.
Authors: Nobuko Hijiya; Melissa M Hudson; Shelly Lensing; Margie Zacher; Mihaela Onciu; Fred G Behm; Bassem I Razzouk; Raul C Ribeiro; Jeffrey E Rubnitz; John T Sandlund; Gaston K Rivera; William E Evans; Mary V Relling; Ching-Hon Pui Journal: JAMA Date: 2007-03-21 Impact factor: 56.272
Authors: Eva Steliarova-Foucher; Charles Stiller; Peter Kaatsch; Franco Berrino; Jan-Willem Coebergh; Brigitte Lacour; Max Parkin Journal: Lancet Date: 2004 Dec 11-17 Impact factor: 79.321
Authors: Smita Bhatia; Harland N Sather; Nyla A Heerema; Michael E Trigg; Paul S Gaynon; Leslie L Robison Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: Heng Xu; Wenjian Yang; Virginia Perez-Andreu; Meenakshi Devidas; Yiping Fan; Cheng Cheng; Deqing Pei; Paul Scheet; Esteban González Burchard; Celeste Eng; Scott Huntsman; Dara G Torgerson; Michael Dean; Naomi J Winick; Paul L Martin; Bruce M Camitta; W Paul Bowman; Cheryl L Willman; William L Carroll; Charles G Mullighan; Deepa Bhojwani; Stephen P Hunger; Ching-Hon Pui; William E Evans; Mary V Relling; Mignon L Loh; Jun J Yang Journal: J Natl Cancer Inst Date: 2013-03-19 Impact factor: 13.506
Authors: C H Pui; D Pei; J T Sandlund; R C Ribeiro; J E Rubnitz; S C Raimondi; M Onciu; D Campana; L E Kun; S Jeha; C Cheng; S C Howard; M L Metzger; D Bhojwani; J R Downing; W E Evans; M V Relling Journal: Leukemia Date: 2009-12-10 Impact factor: 11.528
Authors: Justine M Kahn; Peter D Cole; Traci M Blonquist; Kristen Stevenson; Zhezhen Jin; Sergio Barrera; Randy Davila; Emily Roberts; Donna S Neuberg; Uma H Athale; Luis A Clavell; Caroline Laverdiere; Jean-Marie Leclerc; Bruno Michon; Marshall A Schorin; Jennifer J G Welch; Stephen E Sallan; Lewis B Silverman; Kara M Kelly Journal: Pediatr Blood Cancer Date: 2017-11-01 Impact factor: 3.167
Authors: Kara A Bjur; Chung-Il Wi; Euijung Ryu; Chris Derauf; Sheri S Crow; Katherine S King; Young J Juhn Journal: Mayo Clin Proc Date: 2019-01 Impact factor: 7.616
Authors: David A Siegel; Jun Li; Helen Ding; Simple D Singh; Jessica B King; Lori A Pollack Journal: Pediatr Blood Cancer Date: 2018-10-23 Impact factor: 3.167
Authors: Sheila T Angeles-Han; Courtney McCracken; Steven Yeh; Kirsten Jenkins; Daneka Stryker; Curtis Travers; Kelly Rouster-Stevens; Larry B Vogler; Scott R Lambert; Carolyn Drews-Botsch; Sampath Prahalad Journal: Am J Ophthalmol Date: 2015-08-06 Impact factor: 5.258